Compare Abeona Therapeutics Inc (ABEO) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Gartner Inc — how do they compare? Abeona Therapeutics Inc trades at $7.42 (market cap $424.33M), while Gartner Inc trades at $186.93 (market cap $12.20B). The key difference: Gartner Inc is far larger — about 28.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | IT | |
|---|---|---|
Market Cap | $424.33M | $12.20B |
Sector | Health | Technology |
52-Week High | $7.45 | $264.09 |
52-Week Low | $4.17 | $125.68 |
Enterprise Value | $279.23M | $13.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Gartner (IT) trades at $185.6, up 0.42% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 69.63% gross margin and 12% net income margin, though revenue growth has moderated. Recent news highlights Q2 2026 earnings exceeding expectations and raised full-year EPS guidance, driving positive investor sentiment.
Outlook is supported by valuation discounts (P/E 16.69) and high ROE (113.58%), but risks include consulting segment weakness and negative net cash flow trends. Analysts are mixed with a $172.80 consensus target, suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
